Drug Approval | February 15, 2026
NATCO receives CDSCO approval for Semaglutide in India
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Sputnik Light is the first component of Sputnik V
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Subscribe To Our Newsletter & Stay Updated
